Table 2.

Adverse Events and Outcomes of Treatment.^*

Variable	No. of Patients
Adverse event
Patients who could be evaluated for adverse events	28
GVHD — dose-limiting toxicity
Chronic GVHD of liver	3
Acute GVHD of gut	1
Immune-related adverse events
Death	1
Pneumonitis
Grade 4	1
Grade 2	2
Colitis, grade 3	1
Immune thrombocytopenic purpura, grade 2	1
Diarrhea, grade 2	1
Other adverse events of grade 3 or higher regardless of attribution, or grade 1 or 2 events       at least possibly related to ipilimumab
Acute kidney injury, grade 3	1
Corneal ulcer, grade 3	1
Thrombocytopenia, grade 3 or 4	9
Neutropenia, grade 3 or 4	3
Anemia, grade 3 or 4	2
Pleural effusion, grade 3	1
Limb edema, grade 1 or 2	6
Outcome of treatment
Patients who received maximum administered dose (10 mg/kg)	22
Complete response	5
Partial response	2
Stable disease	6
Progression of disease	9

^*Adverse events were graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.0.